Screener
CRISPR Therapeutics CRSP Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Accrued expenses | 74,932 | 89,407 |
| Deferred revenue, current | 15,344 | 15,771 |
| Accrued tax liabilities | 638 | 1,113 |
| Operating lease liabilities | 18,612 | 18,578 |
| Other current liabilities | 13,113 | 13,113 |
| Total current liabilities | 136,286 | 149,120 |
| Long-term debt | 585,470 | — |
| Operating lease liabilities, net of current portion | 183,560 | 188,168 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's operating lease liabilities (current)?
- CRISPR Therapeutics (CRSP) reported operating lease liabilities (current) of $18.61M in Q1 2026.
- How has CRISPR Therapeutics's operating lease liabilities (current) changed year-over-year?
- CRISPR Therapeutics's operating lease liabilities (current) increased by 6.3% year-over-year, from $17.51M to $18.61M.
- What is the long-term trend for CRISPR Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's operating lease liabilities (current) has grown at a 10.3% compound annual growth rate (CAGR), from $11.36M to $18.58M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about CRISPR Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude